KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Common Equity (2016 - 2026)

Evolent Health has reported Common Equity over the past 12 years, most recently at $415.2 million for Q4 2025.

  • For Q4 2025, Common Equity fell 58.53% year-over-year to $415.2 million; the TTM value through Dec 2025 reached $415.2 million, down 58.53%, while the annual FY2025 figure was $415.2 million, 58.53% down from the prior year.
  • Common Equity for Q4 2025 was $415.2 million at Evolent Health, down from $842.2 million in the prior quarter.
  • Over five years, Common Equity peaked at $1.1 billion in Q1 2023 and troughed at $415.2 million in Q4 2025.
  • A 5-year average of $854.1 million and a median of $877.7 million in 2022 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: surged 3383.78% in 2021 and later crashed 58.53% in 2025.
  • Year by year, Common Equity stood at $693.6 million in 2021, then grew by 23.9% to $859.4 million in 2022, then grew by 24.24% to $1.1 billion in 2023, then decreased by 6.22% to $1.0 billion in 2024, then crashed by 58.53% to $415.2 million in 2025.
  • Business Quant data shows Common Equity for EVH at $415.2 million in Q4 2025, $842.2 million in Q3 2025, and $896.0 million in Q2 2025.